These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32586937)

  • 21. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
    Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
    BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
    Segal NH; Cercek A; Ku G; Wu AJ; Rimner A; Khalil DN; Reidy-Lagunes D; Cuaron J; Yang TJ; Weiser MR; Romesser PB; Stadler ZK; Varghese AM; Ganesh K; Yaeger R; Connell LC; Faleck D; Abou-Alfa GK; Mcauliffe KC; Vaiskauskas P; Solter ML; Ogle M; Adamow MJ; Holland A; Vedantam P; Wong P; Merghoub T; Vakiani E; Hollmann TJ; Juluru K; Chou JF; Capanu M; Erinjeri J; Solomon S; Yamada Y; Kemeny N; Crane CH; Saltz LB
    Clin Cancer Res; 2021 Apr; 27(8):2200-2208. PubMed ID: 33504552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
    Quintela-Fandino M; Holgado E; Manso L; Morales S; Bermejo B; Colomer R; Apala JV; Blanco R; Muñoz M; Caleiras E; Iranzo V; Martinez M; Dominguez O; Hornedo J; Gonzalez-Cortijo L; Cortes J; Gasol Cudos A; Malon D; Lopez-Alonso A; Moreno-Ortíz MC; Mouron S; Mañes S
    Breast Cancer Res; 2020 Nov; 22(1):124. PubMed ID: 33176887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
    J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
    Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Kelly RJ; Lee J; Bang YJ; Almhanna K; Blum-Murphy M; Catenacci DVT; Chung HC; Wainberg ZA; Gibson MK; Lee KW; Bendell JC; Denlinger CS; Chee CE; Omori T; Leidner R; Lenz HJ; Chao Y; Rebelatto MC; Brohawn PZ; He P; McDevitt J; Sheth S; Englert JM; Ku GY
    Clin Cancer Res; 2020 Feb; 26(4):846-854. PubMed ID: 31676670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Ribrag V; Lee ST; Rizzieri D; Dyer MJS; Fayad L; Kurzrock R; Andritsos L; Bouabdallah R; Hayat A; Bacon L; Jiang Y; Miah K; Delafont B; Hamid O; Anyanwu S; Martinez P; Hess B
    Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):309-317.e3. PubMed ID: 33632668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depletion of central memory CD8
    Maeda Y; Wada H; Sugiyama D; Saito T; Irie T; Itahashi K; Minoura K; Suzuki S; Kojima T; Kakimi K; Nakajima J; Funakoshi T; Iida S; Oka M; Shimamura T; Doi T; Doki Y; Nakayama E; Ueda R; Nishikawa H
    Nat Commun; 2021 Dec; 12(1):7280. PubMed ID: 34907192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
    Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
    N Engl J Med; 2018 Feb; 378(6):529-538. PubMed ID: 29414279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
    Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
    Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M
    Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.
    Fujiwara Y; Iguchi H; Yamamoto N; Hayama M; Nii M; Ueda S; Komuro K; Sugimoto M; Vlahovic G; Kozuki T
    Cancer Sci; 2019 May; 110(5):1715-1723. PubMed ID: 30891877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durvalumab for the treatment of non-small cell lung cancer.
    Murakami S
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.
    Lee JY; Kim JW; Lim MC; Kim S; Kim HS; Choi CH; Yi JY; Park SY; Kim BG;
    J Gynecol Oncol; 2019 Nov; 30(6):e112. PubMed ID: 31576697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
    Monge C; Xie C; Myojin Y; Coffman-D'Annibale KL; Hrones D; Brar G; Wang S; Budhu A; Figg WD; Cam M; Finney R; Levy EB; Kleiner DE; Steinberg SM; Wang XW; Redd B; Wood BJ; Greten TF
    Cancer Med; 2024 Feb; 13(3):e6912. PubMed ID: 38205877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
    Millward M; Underhill C; Lobb S; McBurnie J; Meech SJ; Gomez-Navarro J; Marshall MA; Huang B; Mather CB
    Br J Cancer; 2013 May; 108(10):1998-2004. PubMed ID: 23652314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.